| 278.42 2.95 (1.07%) | 11-11 15:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 347.56 | 1-year : | 376.49 |
| Resists | First : | 297.57 | Second : | 322.33 |
| Pivot price | 283.23  |
|||
| Supports | First : | 257.5 | Second : | 214.24 |
| MAs | MA(5) : | 276.76 |
MA(20) : | 280.17 |
| MA(100) : | 251.43 |
MA(250) : | 258.6 |
|
| MACD | MACD : | 2.9 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 20 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 348.89 | Low : | 187.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ WST ] has closed above bottom band by 36.5%. Bollinger Bands are 23.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 276.63 - 278.3 | 278.3 - 279.9 |
| Low: | 266.83 - 268.8 | 268.8 - 270.68 |
| Close: | 272.44 - 275.35 | 275.35 - 278.14 |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Tue, 11 Nov 2025
Transcript : West Pharmaceutical Services, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-11-2025 09 - MarketScreener
Mon, 10 Nov 2025
Ex-Dividend Reminder: West Pharmaceutical Services, Cohen & Steers Tax-advantaged Preferred Securities and Home BancShares - Nasdaq
Thu, 06 Nov 2025
Winners And Losers Of Q3: West Pharmaceutical Services (NYSE:WST) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
Sat, 01 Nov 2025
West Pharmaceutical Services (WST): Exploring Valuation After Q3 Earnings Beat and Upgraded Outlook - Sahm
Thu, 23 Oct 2025
West Pharmaceutical Services Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
Thu, 23 Oct 2025
West Pharmaceutical Services’s (NYSE:WST) Q3 Sales Beat Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 72 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 98.2 (%) |
| Shares Short | 1,520 (K) |
| Shares Short P.Month | 1,680 (K) |
| EPS | 6.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 42.43 |
| Profit Margin | 16.2 % |
| Operating Margin | 21.8 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 16.9 % |
| Qtrly Rev. Growth | 7.6 % |
| Gross Profit (p.s.) | 14.87 |
| Sales Per Share | 41.97 |
| EBITDA (p.s.) | 11.13 |
| Qtrly Earnings Growth | 3.7 % |
| Operating Cash Flow | 694 (M) |
| Levered Free Cash Flow | 251 (M) |
| PE Ratio | 41.25 |
| PEG Ratio | 0 |
| Price to Book value | 6.56 |
| Price to Sales | 6.63 |
| Price to Cash Flow | 28.87 |
| Dividend | 0.2 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|